The lawsuits primarily argue that insulin prices are unreasonably high ... lawsuits is that PBMs drive up patient costs by demanding rebates and fees from pharmaceutical companies.

And that problem is not unique to insulin. PBMs demand rebates and other payments from pharmaceutical companies as a condition of favorable placement for a medicine on the formulary, or list of ...

DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

One example is semaglutide, more commonly known as the two branded weight-loss drugs Ozempic and Wegovy. These were among the ...

slashed the prices of their insulin products. The report further noted that the more credible accusation in these lawsuits is ...

Whether Express Scripts wins its unique defamation lawsuit will depend on whether the PBM can prove the FTC made false ...

The complaint, filed by Express Scripts owner Cigna against the FTC and Commissioner Lina Khan, is seeking the retraction of ...

pharmacy rebates and lost market share with durable medical equipment companies. Despite these challenges, CFO Jereme Sylvain told investors, “with non-insulin opportunities with Stelo and the ...

Then there are the millions of seniors who have already benefitted from Medicare Part D redesign, in part to the new OOP caps ...

Estimated Part D Rebates based on authors’ update of analysis ... The negotiated price of Novolog/Fiasp (insulin aspart) closely resembles the new list price of Novolog after the 2024 voluntary ...

They can also be paired with pumps to automate the insulin delivery process ... including patients taking advantage of rebates more than anticipated and a slower adoption of its G7 than it ...